In patients with metastatic cancer, gut microbiome composition differs between responder and non-responders to immune checkpoint inhibitors. However, there is little consensus on the microbiome taxa associated with response or lack of response. Additionally, recognized confounders of gut microbiome composition have generally not been taken into account. In this study, metagenomic …
Continua a leggere

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on to alternative treatments, including surgery, yet the outcome of patients selected for surgery after checkpoint …
Continua a leggere

Cutaneous adverse events: a predictor of tumor response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients

Cutaneous adverse events (AE) are the most prevalent toxicity under checkpoint-inhibitors in clinical trials. In “real-life” conditions of use, skin toxicities under anti-PD-1 have not been described to date in a large cohort. The objective of this study was to determine the clinical features of skin toxicities in patients with advanced melanoma receiving anti-PD-1 therapy under “real-life”-conditions of …
Continua a leggere

Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma

In patients with cutaneous melanoma (CM), metastasis in a non-sentinel lymph node (non-SLN) is a strong independent adverse prognostic factor. However, patients with a tumor-involved SLN no longer routinely undergo completion lymph node dissection (CLND). We hypothesized that SLN tumor burden may predict non-SLN tumor burden. We compared tumor burden parameters between SLN and non-…
Continua a leggere

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy

Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to another tumor. The aim of this study was to evaluate tumor responses to this combination in a clinical setting. A post-hoc analysis of 3 ongoing immunoradiation trials was performed. Twenty-six …
Continua a leggere